A critical vulnerability in the popular Node.js sandboxing library vm2 allows escaping the sandbox and executing arbitrary ...

At TechCrunch's sold-out StrictlyVC event in San Francisco on Thursday night, we covered a lot of ground in a short time, ...

Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are ...

We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Replimune Group, Inc. is among the best biotech stocks to invest in. TheFly reported on April 13 that Jefferies cut its ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Fintel reports that on April 13, 2026, Wedbush downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Neutral. Analyst Price Forecast Suggests 641.98% Upside As of April 9, ...

In a notable shift in investment sentiment, Replimune Group, Inc. (NASDAQ: REPL) received a “Hold” rating from Roger Song of Jefferies on April 13, 2026. With the stock currently priced at $4.76, the ...

Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...

FDA delivered a second complete response letter rejecting Replimune’s RP1 advanced melanoma treatment The therapy was under review for use with Bristol Myers Squibb’s (BMY) Opdivo immunotherapy ...

FDA has now rejected Replimune’s melanoma immunotherapy RP1 on two separate occasions The drug was under consideration for use with Bristol Myers Squibb’s (BMY) Opdivo therapy Regulators maintained ...